Geniposide

SKU: orb1306089

Description

Geniposide is a bioactive iridoid glycoside known for its neuroprotective, anti-diabetic, and antioxidative properties. Its mechanism involves the regulation of Nrf2 translocation, making it a valuable tool for research in oxidative stress, metabolic disorders, and neurodegeneration in both cellular and animal models.

Research Area

Infectious Disease & Virology, Neuroscience

Key Properties

• CAS Number: 24512-63-8
• MW: 388.3665
• Purity: 99.54% (May vary between batches)
• Formula: C₁₇H₂₄O₁₀
• SMILES: COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)C2C1CC=C2CO
• Target: Beta Amyloid,Influenza Virus
• Solubility: DMSO:247.5 mg/mL (637.28 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.15 mM);H2O:40 mg/mL (102.99 mM)

Bioactivity

• In Vivo:
  Geniposide, administered at doses of 200 and 400 mg/kg, has been observed to significantly reduce blood glucose, insulin, and triglyceride (TG) levels in a dose-dependent manner in diabetic mice. Additionally, it diminishes the expression and enzymatic activity of glucose-6-phosphatase (G6Pase) and glycogen phosphorylase (GP) at both mRNA and protein levels. At dosages of 20.0, 40.0, or 80 mg/kg, geniposide effectively counters the excessive elevation of serum alanine transaminase/aspartate transaminase (ALT/AST) and hepatic lipid peroxidation (LPO) levels induced by alcohol, signifying its potent hepatoprotective properties. Furthermore, it enhances the expression of heme oxygenase-1 (HO-1), mitigating cell apoptosis in primary cultured hippocampal neurons caused by 3-morpholinosydnonimine hydrochloride (SIN-1). In addition to its neuroprotective and hepatoprotective effects, geniposide exhibits anti-thrombotic activity in a photochemistry-induced thromboembolism model in vivo and acts as an effective inhibitor of Nuclear Factor kappa B (NF-κB) activity by preventing IκB degradation.
  Read more...
• In Vitro:
  Geniposide demonstrates multifaceted bioactivities, including antithrombotic, anti-inflammatory, antidiabetic, anti-atherosclerotic, antidepressant effects, and therapeutic potential for Alzheimer's disease (AD), anti-hypertensive, and toxicological effects, alongside managing adverse reactions. It significantly reduces IL-8, IL-1β, and MCP-1 production in OGD-induced brain microvascular endothelial cells, markedly downregulates P2Y14 receptor expression, and inhibits the phosphorylation of RAF-1, MEK1/2, and ERK1/2.
  Read more...
• Cell Research:
  The third passages of brain microvascular endothelial cells (BMECs) are used for the experiment. The BMECs are divided into four groups: (1)normal control group: the normal cultured BMECs without treatment; (2)OGD group: the BMECs injured by OGD according to the above method; (3) geniposide group: the OGD-injured BMECs treated with 33.2 μg/mL geniposide for 6 h; (4)PTX group: the OGD-injured BMECs administrated with 100 ng/mL PTX. PTX, known as an inhibitor of Gi-coupled receptor is used to assess the activation of P2Y14 receptor induced by OGD in this experiment.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Amyloid-β, b Amyloid, bAmyloid, Abeta, 27745-20-6, BetaAmyloid, Beta Amyloid, Inhibitor, Geniposide, InfluenzaVirus, Influenza Virus, inhibit, β-amyloid peptide, βAmyloid, β Amyloid

Compound Identifiers

PubChem CID

107848